"We’re looking at immunotherapy in the adjuvant setting; in oligometastatic disease; in small cell lung cancer; in combination with radiation therapy; and in combination with other immunotherapy and targeted agents, particularly ipilimumab, which works on the CTLA-4 [cytotoxic T-lymphocyte–associated protein 4] area to create a double blockade," Ms. This evidence concerns the gene CTLA4 and small cell lung carcinoma.